Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study - 15/08/18
Summary |
Objectives |
To compare the effectiveness and tolerability of micafungin versus posaconazole during chemotherapy-induced neutropenia in acute leukemia (AL) and myelodysplastic syndrome (MDS).
Methods |
Patients with AL or MDS undergoing chemotherapy were randomized to open-label micafungin 100 mg intravenously daily or posaconazole suspension 400 mg orally twice daily until neutrophil recovery, up to 28 days. Patients were followed for 12 weeks. The primary endpoint was prophylaxis failure (premature discontinuation due to infection, intolerance, adverse event, or death). Time to failure and survival were calculated by Kaplan–Meier analysis.
Results |
From March 2011 to May 2016, 113 patients who received at least 2 doses of prophylaxis were analyzed (58 patients randomized to micafungin and 55 to posaconazole). Prophylaxis failure occurred in 34.5% and 52.7% of patients on micafungin and posaconazole, respectively (P = 0.0118). The median number of days on prophylaxis was 16 [interquartile range (IQR) 12–20] for micafungin and 13 [IQR 6–16] for posaconazole (P = 0.01). Micafungin failures were largely due to antifungal treatment; posaconazole failures were mostly due to gastrointestinal intolerance or adverse effects. IFI incidence and survival were similar between study arms.
Conclusions |
Our data support micafungin as alternative antifungal prophylaxis in patients with AL and MDS.
Le texte complet de cet article est disponible en PDF.Keywords : Immunocompromised hosts, Neutropenia, Invasive fungal infections, Prophylaxis, Posaconazole, Micafungin, Leukemia, Myelodysplastic syndrome
Plan
Vol 77 - N° 3
P. 227-234 - septembre 2018 Retour au numéro
Article précédent
- Acute hepatitis E in French patients and neurological manifestations
- Florence Abravanel, Julie Pique, Elisabeth Couturier, Florence Nicot, Chloé Dimeglio, Sébastien Lhomme, Julie Chiabrando, Karine Saune, Jean-Marie Péron, Nassim Kamar, Solène Evrard, Henriette de Valk, Pascal Cintas, Jacques Izopet, HEV study group
- Diagnosis of invasive aspergillosis in hematological malignancy patients: Performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples
- Sven Heldt, Juergen Prattes, Susanne Eigl, Birgit Spiess, Holger Flick, Jasmin Rabensteiner, Gemma Johnson, Florian Prüller, Albert Wölfler, Tobias Niedrist, Tobias Boch, Peter Neumeister, Heimo Strohmaier, Robert Krause, Dieter Buchheidt, Martin Hoenigl
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?